About Dr. Ye Zhibin
Dr. Ye Zhibin (叶志斌) is a Professor, Doctoral Supervisor, and one of China's leading rheumatologists, based at the Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine. With extensive clinical and research expertise in the diagnosis and management of systemic autoimmune and inflammatory diseases — including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, systemic sclerosis, inflammatory myopathies, vasculitis, and spondyloarthropathies — Dr. Ye is recognized as a senior authority in rheumatology at one of China's most distinguished academic medical centers and one of the highest-volume rheumatology departments in Shanghai.
Rheumatology encompasses a broad and diagnostically challenging spectrum of systemic autoimmune and inflammatory conditions that can affect virtually every organ system — from the joints, skin, and kidneys to the lungs, heart, nervous system, and blood vessels. The optimal management of these conditions requires a level of specialist expertise that goes well beyond general internal medicine: precise diagnosis using clinical assessment, autoantibody profiling, imaging, and tissue biopsy; careful selection and monitoring of immunosuppressive and biological therapies; proactive management of organ complications and disease-related damage; and close coordination with nephrology, pulmonology, cardiology, dermatology, and other specialties for comprehensive, multidisciplinary care. Dr. Ye's clinical practice at Renji Hospital — one of China's foremost rheumatology centers — provides international patients with access to the full spectrum of modern rheumatological care.
Hospital Affiliation: Department of Rheumatology, Renji Hospital
Renji Hospital (仁济医院), affiliated with Shanghai Jiao Tong University School of Medicine, is one of Shanghai's largest and most prestigious academic medical centers. Its Department of Rheumatology is one of the highest-volume and most academically productive rheumatology programs in China, managing a large caseload of SLE, RA, Sjögren's syndrome, systemic sclerosis, vasculitis, and other systemic autoimmune diseases. The department's autoimmune disease laboratory provides comprehensive autoantibody profiling including ANA, anti-dsDNA, anti-Sm, anti-SSA/SSB, anti-Scl-70, anti-centromere, anti-Jo-1 and extended myositis antibody panel, ANCA, antiphospholipid antibodies, and other disease-specific autoantibodies. Its multidisciplinary lupus nephritis program — integrating rheumatology, nephrology, and pathology — is one of the most active in China, with a dedicated lupus nephritis clinic and a high-volume renal biopsy program for lupus nephritis classification and treatment guidance.
Clinical Specialties: What Dr. Ye Zhibin Treats
- Systemic lupus erythematosus (SLE) — diagnosis and disease activity assessment using SLEDAI-2K and BILAG indices; hydroxychloroquine as universal background therapy; corticosteroid induction and tapering; immunosuppressive therapy with mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus, and cyclosporine; belimumab (anti-BLyS) for active SLE; anifrolumab (anti-IFN-α receptor) for moderate-severe SLE; lupus nephritis management including renal biopsy, ISN/RPS classification, and class-specific immunosuppressive protocols; neuropsychiatric SLE management; antiphospholipid syndrome (APS) anticoagulation; pregnancy in SLE including preconception counseling and obstetric monitoring
- Rheumatoid arthritis (RA) — early RA diagnosis and treat-to-target management; conventional synthetic DMARDs (methotrexate, leflunomide, hydroxychloroquine, sulfasalazine); biologic DMARDs including TNF inhibitors (adalimumab, etanercept, infliximab), IL-6 receptor inhibitors (tocilizumab, sarilumab), abatacept, and rituximab; targeted synthetic DMARDs including JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib); DAS28 and CDAI disease activity monitoring; treat-to-target remission strategy; management of RA extra-articular manifestations including interstitial lung disease, vasculitis, and Felty syndrome
- Sjögren's syndrome — primary and secondary Sjögren's syndrome diagnosis using ACR/EULAR 2016 criteria; sicca symptom management; hydroxychloroquine and immunosuppressive therapy for systemic manifestations; management of Sjögren's-associated interstitial lung disease, peripheral neuropathy, renal tubular acidosis, and lymphoma risk; rituximab for severe systemic Sjögren's syndrome
- Systemic sclerosis (scleroderma) — limited and diffuse cutaneous systemic sclerosis diagnosis and management; anti-Scl-70 and anti-centromere antibody profiling; pulmonary arterial hypertension (PAH) screening with echocardiography and right heart catheterization; PAH treatment with endothelin receptor antagonists, PDE-5 inhibitors, and prostacyclin analogues; interstitial lung disease assessment with HRCT and pulmonary function tests; nintedanib and mycophenolate mofetil for SSc-ILD; scleroderma renal crisis management; gastrointestinal dysmotility management
- Inflammatory myopathies — dermatomyositis, polymyositis, immune-mediated necrotizing myopathy (IMNM), and anti-synthetase syndrome diagnosis using myositis-specific antibody panel, EMG, muscle MRI, and muscle biopsy; corticosteroid induction and immunosuppressive maintenance; IVIg for refractory inflammatory myopathy; interstitial lung disease management in anti-synthetase syndrome; malignancy screening for dermatomyositis
- Vasculitis — ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis) diagnosis and management with cyclophosphamide or rituximab induction and azathioprine or rituximab maintenance; giant cell arteritis and polymyalgia rheumatica management with corticosteroids and tocilizumab; Takayasu arteritis diagnosis and immunosuppressive management; Behçet's disease management
- Spondyloarthropathies — ankylosing spondylitis and non-radiographic axial spondyloarthritis diagnosis and management; NSAIDs, TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab), IL-17 inhibitors (secukinumab, ixekizumab), and JAK inhibitors (upadacitinib, tofacitinib) for axial SpA; psoriatic arthritis management; reactive arthritis and enteropathic arthritis
- Crystal arthropathies — gout diagnosis and urate-lowering therapy with allopurinol, febuxostat, and benzbromarone; treat-to-target serum urate management; colchicine, NSAIDs, and corticosteroids for acute gout flares; pegloticase for refractory tophaceous gout; calcium pyrophosphate deposition disease (CPPD) management
Why International Patients Choose Dr. Ye Zhibin and Renji Hospital
International patients seek rheumatology consultation with Dr. Ye Zhibin and Renji Hospital for reasons that reflect both the clinical depth of his autoimmune disease expertise and the comprehensive rheumatology infrastructure available at one of China's foremost rheumatology centers.
For patients with SLE — particularly those with active lupus nephritis, neuropsychiatric SLE, or refractory disease not responding to standard immunosuppression — Dr. Ye's expertise in the full range of SLE therapies including belimumab and anifrolumab, combined with Renji Hospital's dedicated lupus nephritis program and high-volume renal biopsy service, provides access to a level of SLE management sophistication that is available at only a small number of centers in China. The availability of comprehensive autoantibody profiling and renal biopsy with ISN/RPS classification at Renji Hospital enables the precise disease characterization that is essential for optimal lupus nephritis treatment selection.
For patients with RA who have not achieved remission with conventional DMARDs, Dr. Ye's expertise in the full range of biologic and targeted synthetic DMARDs — including the newer JAK inhibitors upadacitinib and filgotinib — provides access to treatment optimization that may not be available at the patient's home institution. The cost of rheumatology consultation and biologic therapy at Renji Hospital is substantially below that of equivalent care in Western healthcare systems, and access to specialist consultation can typically be arranged within days through CMCS.
What to Expect at Your Consultation
Consultations with Dr. Ye Zhibin at Renji Hospital arranged through CMCS begin with a comprehensive review of all prior rheumatology records — including autoantibody panel results, inflammatory markers (CRP, ESR, complement C3/C4), complete blood count, renal function and urinalysis, prior imaging (joint X-rays, MRI, HRCT chest, echocardiography), prior biopsy pathology, current and prior immunosuppressive therapy records, and the patient's rheumatological symptom history and organ involvement assessment. CMCS will arrange certified translation of all medical records and investigation results in advance of the consultation. Dr. Ye will assess the autoimmune disease diagnosis and activity, evaluate the adequacy of current therapy, outline the recommended management strategy with detailed rationale, and coordinate multidisciplinary input from nephrology, pulmonology, and other specialties where appropriate. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Ye's team and the patient's home rheumatologist for continuity of care planning.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking rheumatology consultation with Dr. Ye Zhibin at Renji Hospital. Our services include priority consultation scheduling, certified medical record and laboratory result translation, coordination of autoantibody profiling, imaging, and renal biopsy, on-site interpretation, biologic therapy administration coordination, and written English-language reporting of all findings and recommendations.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 条评论